The efficacy of talimogene laherparepvec (oncolytic viral immunotherapy) and panitumumab (EGFR inhibitor) for the treatment of locally advanced or metastatic cSCC is being researched in another ongoing trial (NCT04163952). The gene discussed is EGFR; the disease is skin squamous cell carcinoma.